CY1106565T1 - Φορεας ανασυνδυασμενου αδενοϊου χοιρου - Google Patents

Φορεας ανασυνδυασμενου αδενοϊου χοιρου

Info

Publication number
CY1106565T1
CY1106565T1 CY20071100603T CY071100603T CY1106565T1 CY 1106565 T1 CY1106565 T1 CY 1106565T1 CY 20071100603 T CY20071100603 T CY 20071100603T CY 071100603 T CY071100603 T CY 071100603T CY 1106565 T1 CY1106565 T1 CY 1106565T1
Authority
CY
Cyprus
Prior art keywords
recombinant
adeno
carrier
nucleotide sequence
methods
Prior art date
Application number
CY20071100603T
Other languages
Greek (el)
English (en)
Inventor
Michael Anthony Johnson
Jeffrey Michael Hammond
Original Assignee
Commonwealth Scientific And Industrial Research Organization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3802849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1106565(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Commonwealth Scientific And Industrial Research Organization filed Critical Commonwealth Scientific And Industrial Research Organization
Publication of CY1106565T1 publication Critical patent/CY1106565T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20071100603T 1997-08-14 2007-05-07 Φορεας ανασυνδυασμενου αδενοϊου χοιρου CY1106565T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO8560A AUPO856097A0 (en) 1997-08-14 1997-08-14 Vector
PCT/AU1998/000648 WO1999008706A1 (en) 1997-08-14 1998-08-14 Recombinant porcine adenovirus vector

Publications (1)

Publication Number Publication Date
CY1106565T1 true CY1106565T1 (el) 2012-01-25

Family

ID=3802849

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100603T CY1106565T1 (el) 1997-08-14 2007-05-07 Φορεας ανασυνδυασμενου αδενοϊου χοιρου

Country Status (17)

Country Link
US (3) US7323177B1 (enExample)
EP (2) EP1825863A1 (enExample)
JP (2) JP4365023B2 (enExample)
KR (1) KR100746524B1 (enExample)
CN (1) CN100366292C (enExample)
AT (1) ATE357250T1 (enExample)
AU (2) AUPO856097A0 (enExample)
BR (1) BR9811184A (enExample)
CY (1) CY1106565T1 (enExample)
DE (1) DE69837390T2 (enExample)
DK (1) DK1007088T3 (enExample)
ES (1) ES2283068T3 (enExample)
ID (1) ID24174A (enExample)
MX (1) MXPA00001562A (enExample)
NZ (1) NZ503039A (enExample)
PT (1) PT1007088E (enExample)
WO (1) WO1999008706A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO856097A0 (en) 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6492343B1 (en) 1998-04-15 2002-12-10 University Of Saskatchewan Porcine adenovirus type 3 genome
FR2789695B1 (fr) * 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
WO2001083737A2 (en) * 2000-05-03 2001-11-08 University Of Guelph Porcine adenovirus type 5 vector and vaccine
WO2002031168A2 (en) * 2000-10-10 2002-04-18 Genstar Therapeutics Minimal adenoviral vector and recombinant vaccines based thereon
SK287969B6 (sk) 2001-03-27 2012-08-06 University Of Saskatchewan Method to culture circovirus
WO2003013598A2 (en) * 2001-08-09 2003-02-20 Lam Dominic M K Novel vaccine compositions and methods of vaccine preparation for veterinary and human diseases
EP1432791B2 (en) 2001-09-06 2013-10-23 Alphavax, Inc. Alphavirus replicon vector systems
JP3949520B2 (ja) * 2001-09-20 2007-07-25 独立行政法人科学技術振興機構 レギュカルチン過剰発現モデル動物
US7569217B2 (en) 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
KR20030054139A (ko) * 2001-12-24 2003-07-02 학교법인 건국대학교 돼지 오제스키병 바이러스의 ｇＤ 유전자를 포함하는재조합 발현 벡터 및 이를 이용한 ＤＮＡ 백신
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
EP1585812B1 (en) 2002-12-13 2017-01-18 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
EP2290054B1 (en) 2002-12-13 2017-03-29 Alphavax, Inc. Alphavirus particles and methods for preparation
JP5016305B2 (ja) 2003-03-20 2012-09-05 アルファヴァックス，インコーポレイテッド 改良されたアルファウイルスレプリコンおよびヘルパー構築物
ATE432285T1 (de) 2003-07-11 2009-06-15 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
CA2567254C (en) 2004-05-18 2012-03-13 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
RU2389506C2 (ru) * 2005-09-09 2010-05-20 Интервет Интернэшнл Б.В. Вакцина против рсv-2
CA2658805A1 (en) * 2006-07-28 2008-01-31 Commonwealth Scientific And Industrial Research Organisation Methods and compositions for increasing tissue tropism of recombinant adenoviral vectors
PL2947149T3 (pl) 2007-06-21 2018-09-28 Alphavax, Inc. Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych
US20100150959A1 (en) * 2008-12-15 2010-06-17 Vectogen Pty Ltd. PCV 2-Based Methods and Compositions for the Treatment of Pigs
US20110135688A1 (en) * 2009-12-04 2011-06-09 Michael Sheppard Methods and Compositions for Increasing Titer of Recombinant Porcine Adenovirus-3 Vectors
CN105688201A (zh) * 2012-05-17 2016-06-22 佐蒂斯有限责任公司 在断奶之前对抗猪繁殖与呼吸综合征（prrs）病毒的有效疫苗接种
AU2015218769B2 (en) * 2014-02-20 2020-09-17 Vaxart, Inc. Formulations for small intestinal delivery
CA2988761A1 (en) 2015-06-12 2016-12-15 Vaxart, Inc. Formulations for small intestinal delivery of rsv and norovirus antigens
CA3047294A1 (en) 2016-12-14 2018-06-21 Zoetis Services Llc Effective vaccination against european strains of porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
CN110904127B (zh) * 2018-09-18 2024-09-20 瓦赫宁恩研究基金会 非洲猪瘟病毒疫苗
CN116981697A (zh) 2021-01-14 2023-10-31 森迪生物科学公司 可分泌有效载荷调节

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4320068C1 (de) 1993-06-17 1994-12-15 Audi Ag Verfahren und Vorrichtung zur Reparatur von Fahrzeugkarosserien aus Leichtmetallteilen
BR9405507A (pt) 1993-07-13 1999-05-25 Rhone Poulenc Rorer Sa Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
EP0770157A4 (en) 1994-07-14 1998-01-07 Union Camp Patent Holding IMPROVED BLEACHING OF A VERY CONCENTRATED LIGNOCELLULOSIC PASTE
FR2725213B1 (fr) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation en therapie genique
ES2105984B1 (es) * 1995-11-30 1998-04-16 Iberica Cyanamid Adenovirus recombinantes que expresan antigenos del virus de la gastroenteritis porcina transmisible (vgpt) y su empleo en la formacion de vacunas.
AUPO856097A0 (en) * 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6492343B1 (en) 1998-04-15 2002-12-10 University Of Saskatchewan Porcine adenovirus type 3 genome

Also Published As

Publication number Publication date
JP4365023B2 (ja) 2009-11-18
AU2011224111A1 (en) 2011-10-13
JP2009213495A (ja) 2009-09-24
CN1275084A (zh) 2000-11-29
HK1032755A1 (zh) 2001-08-03
EP1007088A4 (en) 2003-01-08
DK1007088T3 (da) 2007-06-04
ATE357250T1 (de) 2007-04-15
US7323177B1 (en) 2008-01-29
US20090226485A1 (en) 2009-09-10
WO1999008706A8 (en) 2000-08-10
AUPO856097A0 (en) 1997-09-04
EP1007088A1 (en) 2000-06-14
ID24174A (id) 2000-07-13
DE69837390T2 (de) 2007-08-23
US7785602B2 (en) 2010-08-31
PT1007088E (pt) 2007-05-31
EP1007088B1 (en) 2007-03-21
US20060263387A1 (en) 2006-11-23
NZ503039A (en) 2002-09-27
MXPA00001562A (es) 2004-10-14
BR9811184A (pt) 2001-12-26
WO1999008706A1 (en) 1999-02-25
KR100746524B1 (ko) 2007-08-07
CN100366292C (zh) 2008-02-06
US7473428B2 (en) 2009-01-06
DE69837390D1 (de) 2007-05-03
EP1825863A1 (en) 2007-08-29
ES2283068T3 (es) 2007-10-16
KR20010022882A (ko) 2001-03-26
JP2001514871A (ja) 2001-09-18

Similar Documents

Publication Publication Date Title
CY1106565T1 (el) Φορεας ανασυνδυασμενου αδενοϊου χοιρου
DE69924826T8 (de) Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
HUT77575A (hu) Rekombináns adenovírus vektor és eljárás alkalmazására
ES2069435T4 (es) Composicion de vacuna para vacunar animales, en concreto mamiferos y mas concretamente cerdos o cochinos.
FI950665A0 (fi) Melanoomaan liittyvä antigeeninen polypeptidi, sen epitooppeja ja melanoomarokotteita
DK0885244T4 (da) Peptidimmunogener til vaccination imod og til behandling af allergi
PT851927E (pt) Compostos para imunoterapia e diagnostico de tuberculose
NO20001768D0 (no) Viruskapsomervaksine, fremgangsmåte til fremstilling samt anvendelse derav
PT1317479E (pt) Métodos e composições para doenças associadas à amiloidose
ATE332363T1 (de) Rekombinanter adenovirus welcher eine chimäre penton-base aufweist
ATE389668T1 (de) Tumorantigen
ATE118822T1 (de) Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
ATE300619T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
BR9508645B1 (pt) seqÜÊncia de nucleotÍdeos isolada compreendendo o gene s fipv tendo uma seqÜencia de nucleotÍdeos da cepa 79-1146 fipv, bem como polipeptÍdeo, vacina e composiÇço compreendendo a mesma.
WO2002044202A3 (fr) Peptides immunogeniques mutes derives de r9m, polynucleotides les codant et leurs usages therapeutiques
ES2105984A1 (es) Adenovirus recombinantes que expresan antigenos del virus de la gastroenteritis porcina transmisible (vgpt) y su empleo en la formacion de vacunas.
NO20005321L (no) Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette
WO2002086060A8 (en) Molecular sequence of pig endogenous retrovirus receptors and methods of use